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Neonatal diagnosis of congenital toxoplasmosis is based on the combination of serological and 25 
molecular tests. Maternal screening and treatment differ according to national policies, and may impact 26 
on the sensitivity of diagnostic methods in infants at birth. 27 
In this multicenter study, 115 neonates born to 61 treated (53%) and 54 (47%) untreated women were 28 
retrospectively included in three centers (France, Serbia, USA) to assess the impact of maternal anti-29 
Toxoplasma treatment on the performance of neonatal workup at birth (neosynthesized anti-30 
Toxoplasma IgM, IgA and IgG, and qPCR), using univariate and multivariate approaches.  31 
Independently of the time of maternal seroconversion, the serological techniques were differently 32 
impacted by maternal treatment. The detection of IgM by ISAGA and western-blot (WB) dropped from 33 
90.7% and 88.2% in untreated neonates to 53.3% and 51.9% in treated neonates (p<0.05), whereas IgM 34 
ELISA and IgA ISAGA were not significantly affected by maternal treatment. A two-fold reduction in the 35 
sensitivity of neosynthesized IgG by WB was also observed in case of treatment during pregnancy (37.7% 36 
versus 82.3%). Interestingly, the effect of treatment was shown to be duration-dependent, especially for 37 
IgM detection, when treatment course exceeded 8 weeks, whatever the therapy. The sensitivity of 38 
Toxoplasma PCR in blood was also lowered by maternal treatment from 39.1% to 23.2%.  39 
These results highlight that anti-Toxoplasma therapy during pregnancy may set back biological 40 
evidences of neonatal infection at birth, and underline the need for a careful serological follow-up of 41 

























Toxoplasmosis is a widespread protozoan foodborne infection (1, 2), affecting about one third of 45 
humans, with great differences in prevalence according to geographical areas (3). Hence, public health 46 
policies vary among countries, as the disease burden is diversely appreciated (4, 5). Indeed, Toxoplasma 47 
gondii infection is largely asymptomatic, except in immunocompromised subjects. It can also be 48 
responsible for congenital infection when primary infection is acquired during pregnancy. The only way 49 
to know if a pregnant woman has acquired toxoplasmosis during pregnancy is to determine her 50 
serological status at the beginning of gestation, and repeat serological testing regularly until delivery, if 51 
it shows an absence of protective immunity. Such serological screening has been implemented in some 52 
countries including France, Austria, Belgium, Italy (6–8), to allow early maternal anti-Toxoplasma 53 
therapy, and reduce vertical transmission and severe fetal damages (9–15). The usual treatment consists 54 
in spiramycin (SPI) administration until delivery (16), but if prenatal diagnosis demonstrates the 55 
presence of Toxoplasma DNA in amniotic fluid, it is strongly recommended to switch SPI to the 56 
association of pyrimethamine and sulfadiazine (PYR-SD), as the latter is more potent to reduce fetal 57 
sequelae (17). However, in about 10% of cases, neonates are diagnosed after birth, despite a negative 58 
prenatal diagnosis, and in about 30% of cases, prenatal diagnosis is not performed because of late 59 
infection during gestation (18). Therefore, postnatal diagnosis is essential to diagnose infected neonates 60 
and start treatment, as recommended (19–21).  61 
Clinical and biological work-up for postnatal diagnosis of congenital toxoplasmosis relies on a 62 
combination of methods including, parasite detection in placenta or amniotic fluid collected during 63 
delivery (18), cord blood or newborn blood, by PCR and serological screening (22, 23). The serological 64 
workup is now well-established (6, 21, 24) and usually relies on the detection of specific IgA or IgM in 65 
the neonate serum. As specific IgG antibodies developed by the mother are transferred to the fetal 66 
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compartment, the only way to detect specific IgG synthesized by the neonate himself, is to characterize 67 
anti-Toxoplasma IgG profiles of mother and newborn paired serum samples at birth by western-blotting. 68 
This technique has been added to the routine serological workup since many years in most reference 69 
labs in France (25, 26), and is widely used across Europe. Sensitivity data of these techniques have been 70 
published over years, but show various performances according to studies and countries.  71 
A possible impact of maternal treatment has been suggested for parasite detection in placenta or IgM 72 
detection in neonates, with a higher rate of positive qPCR or positive IgM, respectively, when mothers 73 
had received SPI, compared to PYR-SD (18, 27). However, both studies were conducted in France, where 74 
women usually receive specific therapy during pregnancy, thus the comparison of the sensitivity of 75 
biological tests in neonates born to treated and untreated mothers was not addressed. Recently, Olariu 76 
et al. (28) reported a possible impact of maternal treatment on IgA and IgM detection, but the number 77 
of treated cases was small, and the trimester of infection, which was shown to influence IgA and IgM 78 
antibody detection in the neonate, was not taken into account.  79 
Therefore, the aim of the present study was to assess the impact of maternal anti-Toxoplasma 80 
treatment during pregnancy on the sensitivity of various tests in neonates at birth, using a multivariate 81 
analysis performed on data from three countries with different national policies, i.e. maternal screening 82 
and treatment (France), occasional maternal screening (Serbia), and no maternal screening (USA).  83 
 84 
MATERIALS AND METHODS 85 
Ethics  86 
All analysis were performed during routine work-up, as implemented in the three participating centers. 87 
Data were recorded anonymously. The study design was approved by the local ethics committee of the 88 
University Hospital of Rennes (approval number: #20.08). 89 
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All congenitally infected infants diagnosed over a 10-year period (2010-2019) in the three labs (Dr. Jack 92 
S. Remington Laboratory for Specialty Diagnostics, Palo Alto, CA, USA, (JSRLSD), National Reference 93 
Laboratory for toxoplasmosis from Serbia (CNLTS) and Rennes University Hospital Parasitology lab (RUH-94 
PL)) were retrospectively included if a blood sample had been analyzed at birth or during the first month 95 
of life. Diagnosis of congenital toxoplasmosis relied on a positive prenatal diagnosis (parasite DNA 96 
detection by qPCR on amniotic fluid), and/or detection of specific IgM or IgA in peripheral blood at >7 97 
days of life, or positive Toxoplasma qPCR in peripheral blood or cerebrospinal fluid, or detection of 98 
neosynthesized IgG or IgM by western-blot.  99 
Other relevant data were recorded for analysis: age of gestation at the time of maternal infection, type, 100 
date of onset and duration of anti-Toxoplasma targeted therapy, gender of the newborn, clinical signs at 101 
birth or during the first year of life. When the date of maternal infection could not be known with 102 
accuracy, due to the absence of early serological screening, the estimation was graduated as “1st , 2nd or 103 
3rd trimester”, according to clinical or imaging findings or serological results during pregnancy or 104 
“undetermined” when discovered only after birth. 105 
 106 
Serological methods 107 
Anti-Toxoplasma IgM were detected by ELISA (Platelia Toxo IgM, Biorad, Marnes-la-Coquette, France) 108 
and ISAGA (BioMérieux, Marcy-l’Etoile, France) in CNLTS and RUH-PL, and only by ISAGA in JSRLSD. Anti-109 
Toxoplasma IgA were detected by ISAGA IgA (BioMérieux) in CNLTS and RUH-PL, and by an in-house 110 
ELISA in JSRLSD. Comparison of maternal and neonatal IgG and IgM antibody profiles was performed 111 
using the Toxoplasma WB IgG/IgM assay (LDBIO, Lyon, France) in CNLTS and RUH-PL. 112 
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ELISA indexes for IgM and IgA were positive when ≥1 and negative when <0.8. For performance 113 
calculation, ELISA indexes in grey zone were merged with positive results. ISAGA IgM and IgA scores 114 
were positive when ≥3, according to the manufacturer’s recommendations. When a positive result was 115 
obtained on a cord blood sample using a quantitative test, it was taken into account only if it could be 116 
confirmed on peripheral blood or if WB could rule out contamination of cord blood by maternal IgM 117 
(different profiles).  118 
WB profiles of the mother and her baby were compared to determine if additional bands were observed 119 
in the neonatal serum (neosynthesis by the infected neonate). When cord blood samples were tested, if 120 
the IgM patterns of the mother and baby were similar, then the cord blood was considered 121 
contaminated by the maternal serum and was excluded from the study. When maternal and neonatal 122 
patterns differed by only one faint band, the WB was considered as doubtful. In both instances, if there 123 
were no other arguments in favor of the diagnosis of infection, all tests were repeated on a neonatal 124 
blood sample collected several days later. 125 
 126 
Toxoplasma real-time PCR 127 
For parasite DNA detection, 200 µL of total blood or cerebrospinal fluid (CSF) were extracted using 128 
Qiamp DNA Mini-kit (Qiagen) and 5 µL of DNA was used for amplification. In CNLTS and RUH-PL, the 129 
Toxoplasma-specific quantitative real-time PCR targeted the repetitive rep529 sequence and was carried 130 
out as previously described (18, 29, 30). In JSRLSD, the PCR used two target sequences from the  B1 gene 131 
(22). 132 
 133 
Statistical analysis  134 
All serological and PCR results were included as dichotomous variables (positive / negative), with 135 
borderline test results classified as positive, and were analyzed according to maternal treatment.  136 
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An univariate analysis was performed on population characteristics according to treatment group. The 137 
association of the different test results with qualitative variables (gender, type of sample, trimester of 138 
pregnancy, treatment group) was analyzed using Pearson’s χ2 test or Fisher’s exact test. For continuous 139 
variables (age at time of sampling and duration of treatment) for which the Skewness and Kurtosis tests 140 
showed non-Gaussian distribution, we used the nonparametric Mann–Whitney U test, and the 141 
distributions were displayed as medians with interquartile ranges [25th;75th percentile].  142 
Multivariate analysis was then carried out, and a logistic regression model was set up with each 143 
particular test result as an outcome variable and the trimester of infection, the gender, the newborn age 144 
at sampling (in days), the center, and the maternal treatment (yes / no) as covariates. The duration of 145 
treatment (by categories ≤8 / >8 weeks or in number of weeks) and the type of treatment (SPI or SPI ± 146 
PYR-SD) were further analyzed on the treated group. Only variables that were found to be significant by 147 
univariate analysis, with P < 0.2, were tested forward by stepwise Wald logistic regression. The Odds 148 
ratio ([OR]) and 95% confidence intervals (95% CI) were used to describe the associated factors if P < 149 
0.05.  150 
All statistical tests and procedures were performed using the IBM SPSS 21 statistical package (IBM, NY, 151 
USA).  152 
 153 
RESULTS 154 
Patient file 155 
A total of 115 mother-neonate pairs were included from the 3 centers; 46 from France, 26 from Serbia 156 
and 43 from the USA. Congenital infection was diagnosed antenatally (n=27) and/or after birth on the 157 
basis of neosynthesized antibody detection or positive PCR on newborn samples (Supplementary Table 158 
1). The first positive post-natal test was obtained as soon as birth until one year of age when treatment 159 
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was stopped (Supplementary Table 1). Neonates were aged from 0 to 35 days (median days 3 [1; 11], 160 
when the first blood sample was obtained and included in the study. The time of sampling was earlier in 161 
newborns from treated mothers than from untreated ones, as a result of the follow-up protocol 162 
implemented in case of maternal Toxoplasma infection in Europe (Table 1). Blood samples included 46 163 
cord blood and 69 peripheral blood samples. Most samples were taken before 5 days of life (n=70) 164 
(Table 1). The frequency of detection of specific IgG, IgM, or IgA neosynthesized antibodies did not 165 
depend on the sample type in any of the analyzed diagnostic tests (p>0.05). Maternal seroconversion 166 
occurred during the first (T1), second (T2) and third (T3) trimester in 14 (12.2%), 28 (24.3%) and 36 167 
(31.3%) of cases, respectively, while the date of maternal infection remained unknown in 37 (32.2%), of 168 
which 34 were symptomatic cases (Table 1).  169 
An anti-Toxoplasma-targeted therapy during pregnancy was given to 61 (53.0%) pregnant women. The 170 
proportion of treated women did not differ according to the trimester of seroconversion (Table 1). As 171 
expected, the median duration of treatment was significantly shorter when infection was diagnosed in 172 
T3 (median weeks 5 [2; 7]) in comparison with T2 (median weeks 12 [7.25; 14]) and T1 (median weeks 173 
17.5 [8; 24], p<0.001), respectively. The treatment consisted of SPI alone (n=34), PYR-SD (n=8) or SPI 174 
followed by PYR-SD (n=19). Interestingly, the proportion of infections acquired during the first, second 175 
and third trimester didn’t differ among treated and untreated mothers (Table 1), ruling out a possible 176 
interplay of these two parameters in the interpretation of results. 177 
The incidence of Toxoplasma-related clinical manifestations within the first year of follow-up reached 178 
53.1% (60/113) (Table 1). The main disorders included cerebral lesions, i.e intracranial calcifications, 179 
ventriculomegaly and meningitis in 47/60 (78.3%), ocular lesions in 26/60 (43.3%), and growth 180 
retardation/prematurity in 7/60 (11.7%) neonates. The rate of newborns with clinical signs was 181 
significantly lower when treatment was given during pregnancy (31.1% versus 75.9% in treated and 182 
untreated groups, respectively) (Table 1). 183 
 on N
ovem




















  184 
Maternal treatment is associated with lower frequency of detection of anti-Toxoplasma IgM and IgG 185 
in the neonate, but not of IgA 186 
As a first approach to investigate the impact of maternal anti-Toxoplasma treatment on the results of 187 
diagnostic methods, we calculated the overall sensitivity of each test for prenatally treated and 188 
untreated infants. The overall sensitivity of IgM detection by ELISA and/or ISAGA was lower in infants 189 
born to treated mothers (p<0.0001, Table 2). However, when analyzing separately each technique, the 190 
ELISA-based IgM detection was not affected by treatment, whereas the sensitivity of IgM ISAGA 191 
dropped from 90.7% to 53.3%, when treatment was administered (p<0.0001, Table 2). WB-based IgM 192 
detection was also significantly lower in the treated group, as it was positive in only 55.8%, compared to 193 
88.2% without treatment (p<0.05). This reduction was also observed when gathering doubtful IgM WB 194 
profiles (only one additional faint band obtained with the neonate’s profile, compared to the mother’s 195 
IgM profile) with negative results instead of with the positive ones (p=0.009, data not shown). An above 196 
two-fold reduction of neosynthesized IgG detection by WB was also observed in neonates from treated 197 
mothers, 82.3% versus 37.7% (p<0.01). No significant differences were observed in the detection of 198 
specific IgA (ELISA or ISAGA) according to maternal treatment (Table 2).  199 
To further analyze the differences observed between ISAGA and ELISA for IgM detection, we evaluated 200 
the sensitivity on serum samples analyzed concomitantly with both techniques (Serbian and French 201 
neonates). Results showed that poorer ISAGA sensitivity was associated with maternal treatment, 202 
whereas ELISA sensitivity was even in both treated and untreated groups (Table 3). 203 
As the absence of specific IgM detection in the neonate could be solely due the physiologic 204 
disappearance of antibodies before birth when infection occurred in early pregnancy, we then 205 
performed a multivariate analysis to confirm the results obtained by univariate analysis. Interestingly, 206 
results showed that treatment significantly altered IgM detection by ISAGA and WB (p<0.001 and 207 
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p<0.01, respectively), as well as neosynthetized IgG detection by WB (Table 4), thus confirming 208 
univariate analysis. Multivariate analysis also showed that the trimester of maternal infection influenced 209 
the positivity of these serological tests with more frequent positivity for infections acquired during the 210 
third trimester, while the age of the newborn at the time of sampling had no effect (Table 4 and 211 
Supplementary Table 2). Unexpectedly, the gender was significantly associated with IgM detection, with 212 
male and female infants being most likely to have positive ISAGA IgM, and positive WB IgM, respectively 213 
(Table 4 and Supplementary Table 2). 214 
 215 
The duration of anti-Toxoplasma therapy during pregnancy is unequally associated with reduced 216 
sensitivity of serological tests 217 
To further analyze if the duration of maternal anti-Toxoplasma therapy influenced the sensitivity of 218 
diagnostic methods, we divided the group of 61 infants from treated mothers into two sub-groups, 219 
according to the length of maternal treatment, i.e. ≤8 weeks or >8 weeks of any treatment. 220 
Interestingly, the duration of treatment interfered heterogeneously with the detection of IgM, IgA or 221 
IgG. The detection of specific IgA, regardless of the method, was not altered, but when distinguishing 222 
ISAGA and ELISA, it appeared that ISAGA sensitivity was significantly reduced if treatment course was >8 223 
weeks (p <0.05, Table 5). Sensitivity of IgM detection, whatever the technique used (ELISA, ISAGA or 224 
WB), was dramatically decreased when treatment exceeded 8 weeks (p<0.001, p<0.01, p=0.001, 225 
respectively) (Table 5). Overall, the range of IgM detection decreased from 72-79% to 29-32%, when 226 
treatment lasted ≤8 weeks and >8 weeks, respectively, depending on the method. By contrast, IgG 227 
detection by WB was not significantly modified according to the cut-off of 8 weeks of treatment (Table 228 
5). The duration of treatment seems to have a progressive effect, as illustrated in Fig 1. 229 
Multivariate analysis using the same cut-off of treatment duration (≤8 weeks or >8 weeks), confirmed 230 
these findings (Table 5). Additionally, when taking into account the precise duration of treatment 231 
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(number of weeks), a longer duration of treatment was associated with a lower sensitivity of ISAGA IgA, 232 
as well as of IgM detection by any technique, but no impact on neosynthesized IgG detection by WB 233 
(Table 6). Overall, among the 61 treated neonates, no statistically significant difference (p > 0.05) was 234 
found between neonates treated with SPI or PIR-SD ± SPI, in any serological test results (Table 6).   235 
 236 
Prenatal therapy is associated with decreased sensitivity of the detection of parasite DNA in the 237 
neonate at birth 238 
Eighty-four neonate specimens consisting of blood (n=66) or CSF samples (n=18) were also collected for 239 
Toxoplasma detection by qPCR. The sensitivity dropped from 43.6% to 24.4% in neonates from 240 
untreated and treated mothers, respectively (Table 2). When the precise duration of treatment was 241 
analyzed for each type of treatment, regression analysis showed that there was no effect of SPI alone, 242 




The laboratory diagnosis of congenital toxoplasmosis at birth requires the use of multiple techniques to 247 
prove infection of the neonate, through detecting either antibody neosynthesis by the newborn, or 248 
circulating parasite DNA. Postnatal screening of neonates is paramount in three situations: i) when 249 
evocative clinical signs are present at birth and the mother has not benefited from Toxoplasma 250 
serological screening during gestation, ii) when the mother acquired toxoplasmosis during gestation and 251 
the prenatal diagnosis was negative, and iii) when the mother acquired toxoplasmosis, but prenatal 252 
diagnosis was not performed (late infection during pregnancy).  253 
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As most French women with primary infection during pregnancy are given specific treatment, we 254 
included data of infants from Serbia, where maternal screening has been only recently adopted, and 255 
from the USA, where women are diagnosed and treated only in case of ultrasound anomalies. We chose 256 
to include only early samples, because we wanted to draw conclusions on the effect of maternal on the 257 
early diagnosis of congenital toxoplasmosis. To ensure perfect interpretation of IgM or IgA detection in 258 
cord blood samples, we considered them as positive only if IgM neosynthesis by the newborn was 259 
confirmed by WB, thus ruling out maternal contamination for both IgM and IgA.  260 
Using univariate and multivariate analyses, we found strong evidence that maternal treatment was 261 
associated with a dramatic decrease in the sensitivity of IgM and neosynthesized IgG in the neonate. 262 
Whereas a direct impact of treatment on parasite replication and dissemination was expected, as it is 263 
assumed to reduce parasite loads (27), the demonstration of an impact on antibody synthesis by the 264 
newborn is a novelty. Indeed, it could be hypothesized that the absence of IgM or IgA detection in 265 
newborns was due to a transient synthesis by the fetus, particularly if infection occurred early in 266 
gestation. Indeed, we observed that the positivity of tests was associated with the trimester of infection 267 
(Table 4), with a higher detection rate for infections acquired during the third trimester (Suppl. Table 2), 268 
which also coincides with shorter courses of treatment. However, there was no differences in the time 269 
of infection among treated and untreated mothers (Table 1), thus the time of infection cannot bias the 270 
conclusions on the effect of treatment. Taken together, multivariate analysis clearly demonstrated an 271 
association of treatment with a lower sensitivity of IgM and neosynthesized IgG antibody detection that 272 
could be explained by a delayed synthesis. Additionally, this effect was time-dependent, with an 273 
apparent cut-off of 8 weeks of any treatment (SPI or PYR-SD) for most serological tests. Besides, the 274 
ISAGA technique was more impacted by maternal treatment than the ELISA technique. Since the IgM 275 
ISAGA technique uses “global” antigens from entire parasites, this finding would suggest that maternal 276 
treatment could more likely affect the ability of the fetus to react against surface antigens, than against 277 
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cytoplasmic antigens. Why SPI and PYR-SD administered to the mother had roughly the same effect on 278 
the fetus or neonate antibody response is difficult to explain, as SPI is known as hardly transferring 279 
through the placental barrier. A previous study by Gilbert et al. found no impact of maternal treatment 280 
on the sensitivity of IgM detection by multivariate analysis, but the group treated with PYR-SD was 281 
compared to a control group including both SPI-treated and untreated mothers (31).  282 
In contrast to our results, Naessens et al. investigated IgM detection in peripheral blood samples from 283 
86 congenitally infected newborns and found no significant effect of treatment despite an apparent 284 
decrease of sensitivity (85% in untreated versus 25% in treated, p=0.19) ; they attributed it to the 285 
gestational age of maternal infection rather than to prenatal treatment (32). However, the vast majority 286 
of mothers (75%) had been treated, and the duration of treatment was not known with accuracy, nor 287 
the time of maternal infection, as monthly serological screening was not current practice in most 288 
centers. In a Brazilian study primarily aiming at measuring the duration of IgM synthesis by infected 289 
infants, Lago et al. observed that in 23/28 neonates whose mother had been diagnosed with 290 
seroconversion during pregnancy, IgM were detected during the first month of life. However, the 291 
difference in sensitivity between treated (75%) and untreated (88%) groups was not statistically 292 
significant (p=0.4) (33). 293 
While IgA detection appeared not to be affected by treatment using univariate analysis, there was a 294 
trend towards a time-dependent effect of treatment in infants from treated mothers, irrespective of the 295 
type of treatment. Again, this was significant only with the ISAGA technique, but it must be 296 
acknowledged that there was a small number of samples analyzed with ELISA. Interestingly, it has been 297 
shown in experimental murine infection that specific IgA synthesis was the least affected of all antibody 298 
classes by several anti-Toxoplasma chemotherapeutic regimens (34). 299 
In contrast, despite a significant effect of treatment on the detection of neosynthesized IgG by WB, it 300 
was not related to the duration of maternal treatment. It was not related to the time of sampling, i.e. 301 
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the age of the newborn, either (Table 4). In infants from untreated mothers, neosynthesized IgG were 302 
found in 4/5 (80%) in the early days after birth (0-4 days) and in 7/9 (78%) from day 15 to 35 (data not 303 
shown). Few reports are available on the detection of neosynthesized IgG using WB. In a cohort of 55 304 
neonates, a French multicenter study reported a sensitivity of IgG WB similar to ours at birth (37.7% in 305 
the treated group), increasing to 40% during the first 10 days of life, and to 63.3% between 0.5 and 1.5 306 
months (35). Similar findings were published in Brazil, where the IgG WB was positive in 40% (6/15) of 307 
infected newborns born to treated mothers up to 3 months of age (36). In another Brazilian series of 308 
newborns aged up to 1 month and born to women who had not been given treatment during 309 
pregnancy, the sensitivity of IgG WB reached 73.5 % (130/177), which is not far from the results 310 
obtained in our untreated group (82.3%) (37). However, they found a lower sensitivity of IgM WB (54.8 311 
%) compared to that of IgG WB.  312 
In a previous study, Olariu et al (2019) analyzed IgM and IgA detection in infants from 25 treated and 313 
164 untreated mothers, and similarly found that IgM were less frequently detected in infants of treated 314 
mothers (44%) than of untreated mothers (86.6%, p<0.001)(28). The detection of IgA was not modified 315 
according to maternal treatment, either (p=0.06). However, they did not take into account the 316 
gestational age at the time of maternal infection, which is a major factor impacting the sensitivity of 317 
serological tests (27, 32). In addition, samples were obtained within the first six months of life, whereas 318 
in the present study, we focused on the results obtained early after birth (mean age of 7 days).  319 
It is interesting to note that, in case of maternal anti-Toxoplasma treatment, the detection of IgA was 320 
the most sensitive approach to detect neonatal infection, outperforming IgM and IgG-based screening 321 
(68.4% versus 59% and 38%, respectively), while it was less sensitive in untreated cases.  322 
Still, the overall sensitivity of IgA and IgM detection (71.8% and 73.9%, respectively) is quite high 323 
compared to previous reports, which showed sensitivity ranges from 47.8 to 72.5% and 44 to 67.5%, for 324 
IgA and IgM, respectively, irrespective of the technique (24, 27, 31, 35).  325 
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Whereas the contribution of PCR testing in AF has been extensively evidenced for prenatal diagnosis, 326 
the use of PCR on newborn blood or CSF at birth has been sparsely investigated (22). In our cohort, the 327 
sensitivity of blood PCR was low (28.6%) but it is interesting to note that it ranged from 23% to 39% in 328 
treated and untreated infants, respectively. Unexpectedly, while univariate analysis was significant, 329 
multivariate analysis showed that treatment onset did not impact PCR positivity. However, among 330 
treated neonates, the longer the treatment, the lower the sensitivity of PCR, provided that the 331 
treatment was PYR-SD, which is in agreement with the expected in utero anti-parasitic effect of this bi-332 
therapy. The trimester of pregnancy had no impact on the positivity of PCR, while it might be expected 333 
to find more positive PCR results when infection occurred at the end of pregnancy, due to a shorter 334 
course of treatment. These findings may suffer from a bias of center, as the proportion of positive cases 335 
was higher in the JSRLSD (38% versus 23% in RUHPL), but 37 cases were excluded from the multivariate 336 
analysis because of missing data, thus the power of the analysis may have been impaired.  337 
The strength of our study is that it was performed on a well-balanced cohort of prenatally-treated and 338 
untreated infants, diagnosed prospectively in three reference centers. A limitation can result from the 339 
uncertainty of the time of maternal infection in some US cases, as no serological follow-up was 340 
undertaken, which led us to discard 32% of cases for the multivariate analysis.  341 
Taken together, we provide evidence that anti-Toxoplasma therapy in the mother may contribute to set 342 
back serological confirmation in the neonate, and underlines the need for careful serological follow-up 343 
of neonates even if the workup at birth is normal. We also recall that prenatal diagnosis can detect at 344 
most 90% of infected fetus, thus postnatal serological follow-up is essential.  345 
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LEGENDS TO FIGURES 353 
Fig. 1: Sensitivity of diagnostic tests according to the duration of treatment. 354 
Statistical significance was graduated as * (p<0.05) and ** (p<0.01). Data obtained for ELISA IgA are not 355 
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Table 1. Population characteristics (N=115) and comparison according to treatment group 468 
 469 




 No (N = 54) Yes (N = 61) p 
Sex ratio (M/F) 0.69 (22/32) 1.10 (32/29) 0.209, ns 
Type of blood sample, n (%)   <0.0001 
 Cord blood (n=46) 4 (7.4) 42 (68.8)  
 Peripheral blood (n=69) 50 (92.6) 19 (31.1)  
Time of blood sampling, median 
(interquartile range) 
10 (4-17) 1 (0-3) <0.0001 
        0-4 days of life (n=70), n (%) 16 (29.6) 54 (88.6)  
        5-14 days of life (n=21), n (%) 20 (37.0) 1 (1.6)  
        15-35 days of life (n=24), n (%) 18 (33.3) 6 (9.8)  
Trimester of maternal infection, n (%)   0.063, ns 
 TI (n=14) 4 (7.4) 10 (16.4)  
 TII (n=28) 2 (3.7) 26 (42.6) 
 TIII (n=36) 11 (20.4) 25 (41.0) 
 ND (n=37) 37 (68.5) 0  
Clinical manifestation during the first 
year of life, n (%) 
  <0.0001 
 Yes (n=60) 41 (75.9) 19 (31.1)  
 No (n=53) 11 (20.4) 42 (68.9)  
 ND (n=2) 2 (3.7) 0  
Type of treatment, n (%) na  na 
 SPI alone  34 (55.7)  
 SPI then PYR-SD  19 (31.1)  
 PYR-SD alone  8 (13.1)  
$ Pearson’s 2 test or + Fisher’s exact test compared distributions in treated and untreated groups 470 
na: not applicable; nd: not determined; ns: not significant; SPI: spiramycin; PYR-SD: pyrimethamine-sulfadiazine  471 
 472 
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Table 2: Sensitivity of serological tests and qPCR in newborns according to treatment group (N=115) 474 










p (Fisher’s test) 
 
IgA¤ (ELISA or ISAGA)  71.8 (79/110) 75.5 (40/53) 68.4 (39/57) 0.416 
     IgA ELISA 72.1 (31/43) 73.0 (27/37) 66.7 (4/6) 1 
     IgA ISAGA 71.6 (48/67) 81.2 (13/16) 68.6 (35/51) 0.526 
IgM¤ (ELISA or ISAGA) 73.9 (85/115) 90.7 (49/54) 59.0 (36/61) 0.0001 
     IgM ELISA 59.2 (42/71) 68.8 (11/16) 56.4 (31/55) 0.564 
     IgM ISAGA 71.1 (81/114) 90.7 (49/54) 53.3 (32/60) <0.0001 
IgM WB 63.8 (44/69) 88.2 (15/17) 55.8 (29/52) 0.0198 
IgG WB 48.6 (34/70) 82.3 (14/17) 37.7 (20/53) 0.0018 
qPCR 33.3 (28/84) 43.6 (17/39) 24.4 (11/45) 0.104 
     Blood 28.8 (19/66) 39.1 (9/23) 23.2 (10/43) 0.254 
     CSF 50.0 (9/18) 50.0 (8/16) 50.0 (1/2) 1 
¤ IgM and IgA ELISA values in the grey zone were grouped with positive results 475 
Na, not applicable 476 
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Table 3. Compared sensitivity of ISAGA and ELISA assays for IgM detection (N=70) according to 478 







£This analysis included only neonates for whom both IgM ELISA and IgM ISAGA were performed on the same 486 
sample 487 
¤ IgM ELISA values in the grey zone were grouped with positive results 488 
 489 
  490 
 Sensitivity according to maternal treatment 
% (n/N) £ 
p (Fisher test) 
 Treated Untreated  
IgM ELISA¤ 55.6 (30/54) 68.8 (11/16) 0.400 
IgM ISAGA 51.9 (28/54) 81.2 (13/16) 0.045 
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Table 4. Multivariate analysis of the effect of treatment, trimester of maternal infection, and age at 491 
blood sampling on the sensitivity of diagnostic tests 492 
 493 
*blood or CSF 494 
ND; not determined because the p value in univariate analysis was <0.2 (results not shown) 495 







             Treatment 
            
p 
OR (95% CI) 
Trimester of maternal 
infection 
p   
OR (95% CI) 
Gender 
male  
p   
OR (95% CI) 
Newborn age  
 
p   





























0.292  (0.068 0.990) 
























Table 5. Sensitivity of serological tests and qPCR in newborns from treated mothers (N = 61), and 497 
comparison according to treatment duration ≤8 or >8 weeks 498 
 499 
Diagnostic test Sensitivity according to the 




Multivariate analysis §  
 ≤ 8 wks 
N = 33 
> 8 wks 
N = 28 
p p OR [95% CI] 
IgA (ELISA or ISAGA) (N=57) 78.1 (25/32) 56.0 (14/25) 0.091 0.079 na 
     IgA (ELISA) (N=6) 33.3 (1/3) 100 (3/3) 1 nd na 
     IgA (ISAGA) (N=51) 82.8 (24/29) 50.0 (11/22) 0.017 0.009 0.161 [0.041-0.629] 
IgM (ELISA or ISAGA) (N=61) 75.6 (25/33) 39.3 (11/28) 0.005 0.04 0.208 [0.070-0.619] 
     IgM (ELISA) (N=55) 76.7 (23/30) 32.0 (8/25) 0.001 0.048 0.288 [0.083-0.972] 
     IgM (ISAGA) (N=60) 71.9 (23/32) 32.1 (9/28) 0.004 0.035 0.117   [0.026-0.517] 
IgM (WB) (N=52) 78.6 (22/28) 29.2 (7/24) 0.001 0.001 0.112 [0.032-0.396] 
IgG (WB) (N=53) 46.4 (13/28) 28.0 (7/25) 0.256 nd na 
qPCR # (N=45) 30.8 (8/26) 15.8 (3/19) 0.309 nd na 
na: not applicable 500 
nd: not determined because the p value in univariate analysis was <0.2 501 
$ Fischer’s exact test 502 
§ multivariate analysis was done using the treatment duration as qualitative variable (>8 or ≤8 weeks); data for 503 
other covariates are not shown  504 
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Table 6: Sensitivity of diagnostic tests according to treatment duration (weeks) 506 
Diagnostic 
test 
Statistical significance of treatment duration in weeks on diagnostic tests* 
 
Any treatment (N=61) 
SPI (N = 34) PYR-SD ± SPI (N =27) 











Regression analysis  
p  






p   
OR [95% CI] 
IgA (ISAGA) 0.052 0.047 
0.929 [0.864-0.999]  
0.069 0.056 0.375 ND 
IgM (ELISA)  0.000 0.001 
0.518 [0.581-0.962] 
0.052 0.052 0.346 ND 






IgM (WB) 0.000 0.001 
0.857 [0.761-0.965] 
0.000 0.027 
0.872 [0.758 -0.901] 
0.000 0.023 
0.845 [0.730-0.977] 
IgG (WB) 0.149 0.155 0.435 ND 0.755 ND 
qPCR 0.124 0.193 0.615 ND 0.065 0.042 
0.102 [0.011-0.902] 
*data for other covariates are not shown 507 
§ comparison of the mean durations of treatment in patients with negative and positive tests results   508 
# calculated on N= 51, 55, 60, 52, 53 and 45, respectively for the various tests 509 
ND: not determined because the p value in univariate analysis was <0.2 510 
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